Analysts at StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Get Free Report) in a research report issued to clients and investors on Sunday. The brokerage set a “hold” rating on the stock.
Brooklyn ImmunoTherapeutics Price Performance
Shares of BTX stock opened at $1.01 on Friday. The firm’s 50-day simple moving average is $1.49 and its 200-day simple moving average is $1.82. Brooklyn ImmunoTherapeutics has a 1-year low of $0.17 and a 1-year high of $10.10. The firm has a market cap of $59.41 million, a P/E ratio of -0.44 and a beta of 4.61.
About Brooklyn ImmunoTherapeutics
Featured Articles
- Five stocks we like better than Brooklyn ImmunoTherapeutics
- Financial Services Stocks Investing
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- Are Penny Stocks a Good Fit for Your Portfolio?
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- What is a Dividend King?
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.